Skip to main content
Book cover

Bone Metastases from Prostate Cancer pp 193–207Cite as

Bone-Seeking Radionuclide for Therapy

  • 1297 Accesses

Abstract

Ionising radiation is utilised in a variety of situations in the management of prostate cancer. Beyond the scope of this book is the use of brachytherapy and external beam radiotherapy (EBRT) as efficacious, radical treatment modalities in the management of localised prostate cancer. Earlier chapters have covered the use of EBRT as a therapeutic option for the treatment of symptomatic bone metastases. This chapter focuses on the place of radionuclide therapy for the management of bone metastases. Recent development of radium-223 dichloride has reinvigorated this field of therapy. Here, analysis is made of the history of radionuclides and their current role in the modern treatment paradigm; the chapter closes by horizon-scanning for the potential future applications of radionuclide therapy, both as part of novel combinations with other agents and in new settings beyond current licensed indications.

Keywords

  • Alpha Particle
  • Linear Energy Transfer
  • Radionuclide Therapy
  • Abiraterone Acetate
  • Beta Particle

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-42327-2_16
  • Chapter length: 15 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-42327-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)
Learn about institutional subscriptions

Bibliography

  1. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298–1312

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  2. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91(4):718–729

    CAS  CrossRef  PubMed  Google Scholar 

  3. Atkins GJ, Findlay DM (2012) Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int 23(8):2067–2079

    CAS  CrossRef  PubMed  Google Scholar 

  4. Kassis A, Adelstein SJ (2005) Radiobiologic principles in radionuclide therapy. J Nucl Med 46(no.1 suppl):4s–12s

    PubMed  Google Scholar 

  5. Sofou S (2008) Radionuclide carriers for targeting of cancer. Int J Nanomedicine 3(2):181–199

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  6. Joiner M, Van Der Kogel A (eds) (2009) Basic clinical radiobiology, 4th edn. Hodder Arnold, London

    Google Scholar 

  7. Turner PG, O’Sullivan JM (2015) (223)Ra and other bone-targeting radiopharmaceuticals-the translation of radiation biology into clinical practice. Br J Radiol 88(1050):20140752

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  8. Friedell HL, Storaasli JP (1950) The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther 64(4):559–575

    CAS  PubMed  Google Scholar 

  9. Nair N (1999) Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 40(2):256–261

    CAS  PubMed  Google Scholar 

  10. Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6(6):392–400

    CAS  CrossRef  PubMed  Google Scholar 

  11. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM et al (1991) A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27(8):954–958

    CAS  CrossRef  PubMed  Google Scholar 

  12. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14(7–8):349–351

    CAS  PubMed  Google Scholar 

  13. Russ Knapp FF Jr, Mirzadeh S, Beets AL, O’Doherty M, Blower PJ, Verdera ES et al (1998) Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot 49(4):309–315

    CrossRef  Google Scholar 

  14. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J et al (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 27(2):123–130

    CAS  CrossRef  PubMed  Google Scholar 

  15. O’Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S et al (2002) High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 86(11):1715–1720

    CrossRef  PubMed  PubMed Central  Google Scholar 

  16. O’Sullivan JM, Norman AR, McCready VR, Flux G, Buffa FM, Johnson B et al (2006) A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging 33(9):1055–1061

    CrossRef  PubMed  Google Scholar 

  17. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ et al (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16(4):1574–1581

    CAS  PubMed  Google Scholar 

  18. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE et al (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63(5):940–945

    CrossRef  PubMed  Google Scholar 

  19. Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56(5):1397–1404

    CrossRef  PubMed  Google Scholar 

  20. Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H et al (2003) Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Eur Urol 44(5):519–526

    CAS  CrossRef  PubMed  Google Scholar 

  21. Tu S, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC et al (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357(9253):336–341

    CAS  CrossRef  PubMed  Google Scholar 

  22. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  23. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  24. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A et al (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69–76

    CAS  CrossRef  PubMed  Google Scholar 

  25. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G et al (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nuclear Med JNM 43(1):79–86

    CAS  PubMed  Google Scholar 

  26. Lam MG, Bosma TB, van Rijk PP, Zonnenberg BA (2009) (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging 36(9):1425–1433

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  27. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

    CAS  CrossRef  PubMed  Google Scholar 

  28. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154

    CrossRef  PubMed  Google Scholar 

  29. van Dodewaard-de Jong JM, de Klerk JM, Bloemendal HJ, van Bezooijen BP, de Haas MJ, Wilson RH et al (2011) A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging 38(11):1990–1998

    CrossRef  Google Scholar 

  30. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH (2003) Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med 44(2):252–259

    CAS  PubMed  Google Scholar 

  31. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin J et al (2005) First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11(12):4451–4459

    CAS  CrossRef  PubMed  Google Scholar 

  32. Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF et al (2013) Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 40(9):1384–1393

    CAS  CrossRef  PubMed  Google Scholar 

  33. Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A et al (2012) A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48(5):678–686

    CAS  CrossRef  PubMed  Google Scholar 

  34. Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG et al (2013) A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 63(2):189–197

    CAS  CrossRef  PubMed  Google Scholar 

  35. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8(7):587–594

    CAS  CrossRef  PubMed  Google Scholar 

  36. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al (2013; 2015) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223

    Google Scholar 

  37. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15(7):738–746

    CAS  CrossRef  PubMed  Google Scholar 

  38. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J et al (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15(12):1397–1406

    CAS  CrossRef  PubMed  Google Scholar 

  39. Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B et al (2015) A Phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med 56(9):1304–1309

    CAS  CrossRef  PubMed  Google Scholar 

  40. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN et al (2014) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology Feb 2015;16(2):152–160

    Google Scholar 

  41. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al (2011; 2015) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005

    Google Scholar 

  42. Scher HI, Fizazi K, Saad F, Taplin M, Sternberg CN, Miller K, et al (2012; 2015) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197

    Google Scholar 

  43. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014; 2015) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Queen’s University Belfast, University Road, Belfast, Ulster, BT7 1NN, Ireland

    Joe O’Sullivan & Phil Turner

Authors
  1. Joe O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phil Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joe O’Sullivan .

Editor information

Editors and Affiliations

  1. University of Verona, Director of Metabolic Bone Diseases and Osteoncology Unit, Internal Medicine Department of Medicine, Verona, Italy

    Francesco Bertoldo

  2. IRCCS AOU San Martino-IST National Cancer Research Institute, Department of Internal Medicine and Medical specialties (DIMI), School of Medical and Pharmacological Sciences, University of Genoa, Academic Unit of Medical Oncology, Department of Oncology (DIPOE), Genoa, Italy

    Francesco Boccardo

  3. Humanitas Gavazzeni Clinic, Clical Scientific Director Department of Nuclear Medicine, Bergamo, Italy

    Emilio Bombardieri

  4. Veneto Institute of Oncology IOV - IRCCS, Nuclear Medicine and Molecular imaging Unit, Padova, Italy

    Laura Evangelista

  5. Radiation Oncology 1 and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Oncology and Hemato-oncology, Università di Milano, Milan, Italy

    Riccardo Valdagni

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

O’Sullivan, J., Turner, P. (2017). Bone-Seeking Radionuclide for Therapy. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42327-2_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42326-5

  • Online ISBN: 978-3-319-42327-2

  • eBook Packages: MedicineMedicine (R0)